Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
New Managers July 2012

Servicers' Spot IMS: New funds must not be disheartened by the regulatory challenges

Peter Moore

Peter Moore is head of compliance and regulation for the IMS Group, a global compliance group for the asset management and securities industry. Its clients include many of the world's largest hedge fund managers, private equity firms, fund of funds managers, family offices and institutional pension fund managers.

He talked to Opalesque about the regulatory and compliance challenges that new hedge funds are facing now, and advises them not to be discouraged by the new, demanding requirements.

"Over the last few years, column inches have been taken up by the many political and regulatory responses to the financial crisis," he said. "We have the responses in the US with the Dodd-Frank Wall Street Reform and Consumer Protection Act, and then in the UK where there is a very large number of new initiatives and new directives coming from Europe in order to respond to the financial crisis, such as those relating to short selling, central clearing for OTC derivatives and a new regime for some managers and distributors of alternative funds."

In his career, he has never seen such a level of change. But this is not a brick wall.

"The key message to any start-up is that none of the challenges, whether they be old or new regulatory challenges, are insurmountable. They all have a few basic themes which are: integrity within the financial market, the fair treatment of clients and investors and the supply of information. Despite all the regulation and the cost to comply with it, if a new firm has a business case for starting up a new venture, a new fund, it must not be distracted or disheartened by the regulatory challenges it faces. These are all surmountable with the right ad......................

To view our full article please login

This article was published in Opalesque's New Managers a top-down monthly analysis, news and research publication on the global emerging manager space.
New Managers
New Managers
New Managers

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for